CU20110246A7 - Ácido benzoico, derivados de ácido benzoico y conjugados de ácido heteroaril carboxílico de hidrocodona, profármacos, métodos para elaborar y utilizar los mismos - Google Patents

Ácido benzoico, derivados de ácido benzoico y conjugados de ácido heteroaril carboxílico de hidrocodona, profármacos, métodos para elaborar y utilizar los mismos

Info

Publication number
CU20110246A7
CU20110246A7 CU20110246A CU20110246A CU20110246A7 CU 20110246 A7 CU20110246 A7 CU 20110246A7 CU 20110246 A CU20110246 A CU 20110246A CU 20110246 A CU20110246 A CU 20110246A CU 20110246 A7 CU20110246 A7 CU 20110246A7
Authority
CU
Cuba
Prior art keywords
hydrocodone
benzoic acid
methods
acid
conjugates
Prior art date
Application number
CU20110246A
Other languages
English (en)
Other versions
CU24128B1 (es
Inventor
Bindu Bera
Andrea K Martin
Jaroslaw Kanski
Gouchen Chi
Christal Mickle
Sven Guenther
Travis Mickle
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43411452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20110246(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of CU20110246A7 publication Critical patent/CU20110246A7/es
Publication of CU24128B1 publication Critical patent/CU24128B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La tecnología descrita actualmente proporciona composiciones que comprenden ácidos aril carboxílicos químicamente conjugados con hidrocodona (morfinan-6-ona, 4, 5-alfa-epoxi-3-metoxi-17-metil) para formar profármacos/composiciones novedosas de hidrocodona, que incluyen benzoatos y ácidos heteroaril carboxílicos, que tienen un potencial reducido para el abuso de hidrocodona. La presente tecnología también proporciona métodos para tratar pacientes, equipos farmacéuticos y métodos para sintetizar conjugados de la presente tecnología.
CU2011000246A 2009-07-02 2010-07-01 Compuesto de benzoato conjugado a la hidrocodona (bz-hc) CU24128B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22271809P 2009-07-02 2009-07-02
PCT/US2010/040775 WO2011002991A1 (en) 2009-07-02 2010-07-01 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof

Publications (2)

Publication Number Publication Date
CU20110246A7 true CU20110246A7 (es) 2012-04-15
CU24128B1 CU24128B1 (es) 2015-09-29

Family

ID=43411452

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000246A CU24128B1 (es) 2009-07-02 2010-07-01 Compuesto de benzoato conjugado a la hidrocodona (bz-hc)

Country Status (21)

Country Link
US (14) US8759368B2 (es)
EP (2) EP2448407B1 (es)
JP (1) JP5442862B2 (es)
KR (5) KR101655972B1 (es)
CN (1) CN102480959B (es)
AU (1) AU2010266205B2 (es)
BR (1) BR112012000569B8 (es)
CA (1) CA2766388C (es)
CL (1) CL2011003347A1 (es)
CO (1) CO6480991A2 (es)
CR (1) CR20110688A (es)
CU (1) CU24128B1 (es)
IL (2) IL217096A (es)
MX (1) MX2012000128A (es)
MY (1) MY153046A (es)
NZ (1) NZ597235A (es)
RU (1) RU2505541C2 (es)
SG (1) SG177445A1 (es)
UA (1) UA102916C2 (es)
WO (1) WO2011002991A1 (es)
ZA (2) ZA201109438B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US8871780B2 (en) * 2009-07-02 2014-10-28 Kempharm, Inc. Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, method of making and use thereof
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
SG11201401856VA (en) * 2011-10-26 2014-05-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
KR101454515B1 (ko) * 2012-12-04 2014-10-23 바이오스펙트럼 주식회사 베라트릭 산 또는 이의 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 피부상태 개선용 조성물
WO2014138740A1 (en) 2013-03-08 2014-09-12 Johnson Matthey Public Limited Company Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
EP3114601B1 (en) * 2014-03-07 2020-01-08 British Telecommunications public limited company Access control for a resource
WO2016064914A1 (en) 2014-10-20 2016-04-28 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
RU2683317C2 (ru) * 2014-11-25 2019-03-28 Кемфарм, Инк. Конъюгаты оксикодона с бензойной кислотой, производными бензойной кислоты и гетероарилкарбоновой кислотой
RU2683274C2 (ru) 2014-12-02 2019-03-27 Кемфарм, Инк. Бензойная кислота, производные бензойной кислоты и конъюгаты гетероарилкарбоновой кислоты и оксиморфона, их пролекарства, способы получения и применение
KR20160097867A (ko) * 2015-02-10 2016-08-18 삼성전자주식회사 영상 표시 장치 및 영상 표시 방법
KR101669887B1 (ko) * 2015-03-05 2016-10-28 부산대학교 산학협력단 벤조인산을 유효성분으로 포함하는 임신 촉진용 조성물
US10226456B2 (en) 2015-04-27 2019-03-12 3St Research Llc Methods and compositions for preventing opioid abuse
US10017519B2 (en) 2015-04-27 2018-07-10 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof
US10449190B2 (en) * 2015-04-27 2019-10-22 John K. Thottathil Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
AU2016332071B2 (en) 2015-10-01 2019-04-18 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
KR101800834B1 (ko) 2016-07-20 2017-12-21 중앙대학교 산학협력단 아나카딕산을 유효성분으로 하는 배뇨 장애 예방 및 치료용 조성물
US10406153B2 (en) 2016-08-31 2019-09-10 Noramco, Inc. Process for the preparation of benzhydrocodone hydrochloride
EP3595663A4 (en) 2017-03-17 2021-01-13 Elysium Therapeutics, Inc. MULTIPLE SUBUNITY OPIOID PRODRUGS WITH RESISTANCE TO OVERDOSE AND ABUSE
WO2018191477A1 (en) * 2017-04-14 2018-10-18 Kempharm, Inc. Dextrorphan prodrugs and processes for making and using them
WO2018191474A1 (en) * 2017-04-14 2018-10-18 Kempharm, Inc. Levorphanol prodrugs and processes for making and using them
US11234975B2 (en) 2017-04-14 2022-02-01 Kempharm, Inc. Levorphanol prodrugs and processes for making and using them
AU2019224127B2 (en) * 2018-02-23 2021-12-09 Rhodes Technologies Novel opioid compounds and uses thereof
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020012245A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
AU2020397821B2 (en) * 2019-12-02 2024-07-25 Academia Sinica PDIA4 inhibitors and use thereof for inhibiting ß-cell pathogenesis and treating diabetes

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB320749A (es)
US1731152A (en) * 1925-10-27 1929-10-08 Firm C H Boehringer Sohn Process for the manufacture of derivatives of dihydrocodeinone or its substitution products
AT229496B (de) 1961-03-08 1963-09-25 Lannacher Heilmittel Verfahren zur Darstellung des neuen Nicotinsäureesters des Dihydrohydroxycodeinons
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
SE9003665D0 (sv) 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
GB9423542D0 (en) 1994-11-22 1995-01-11 Marples Brian A Pharmaceutical compounds
GB2307833B (en) 1995-12-01 2000-06-07 Geco As A data compression method and apparatus for seismic data
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
US7091040B1 (en) * 1999-01-04 2006-08-15 Innovata Plc P450/acetaminophen genetically directed enzyme prodrug therapy (GDEPT)
MXPA02007252A (es) * 2000-01-28 2003-01-29 Rohm & Haas Compuestos farmaceuticos con propiedades mejoradas.
JP4814486B2 (ja) 2001-06-05 2011-11-16 シヴィダ・インコーポレイテッド 持続放出性鎮痛性化合物
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
KR100822498B1 (ko) * 2002-02-22 2008-04-16 샤이어 엘엘씨 규제된 물질의 남용을 방지하기 위한 새로운 서방성 약학화합물
US20040058946A1 (en) 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
TW200500067A (en) 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
JP2006520392A (ja) 2003-03-13 2006-09-07 コントロールド・ケミカルズ・インコーポレーテッド 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法
EP1782834A3 (en) 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
EA008864B1 (ru) 2003-09-30 2007-08-31 Нью Ривер Фармасьютикалз Инк. Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
CA2541371C (en) 2003-10-03 2014-12-16 Atul M. Mehta Extended release formulations of opioids and method of use thereof
US20050203115A1 (en) 2004-03-10 2005-09-15 Sancilio Frederick D. Narcotic-NSAID ion pairs
PT1751087E (pt) 2004-06-04 2012-09-10 Xenoport Inc Derivados de levodopa e as suas composições e utilizações
US7348430B2 (en) 2005-01-21 2008-03-25 Acura Pharmaceuticals, Inc. Production of opioid analgesics
EP2007762A2 (en) 2006-04-10 2008-12-31 Shire LLC Mono and di-substituted oxycodone compounds and compositions
MX2008014794A (es) * 2006-05-26 2009-04-08 Pharmacofore Inc Liberacion controlada de opioides fenolicos.
US20080090771A1 (en) * 2006-10-06 2008-04-17 Shire Llc Abuse-resistant hydrocodone compounds, compositions and methods of using the same
CA2666582C (en) * 2006-10-20 2014-09-09 Mcneil-Ppc, Inc. Acetaminophen / ibuprofen combinations
WO2009079013A1 (en) * 2007-12-17 2009-06-25 Mallinckrodt Inc. Processes for the production of (+)-'nal' morphinan compounds
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US8871780B2 (en) 2009-07-02 2014-10-28 Kempharm, Inc. Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, method of making and use thereof
US8623888B2 (en) * 2009-07-15 2014-01-07 Mallinckrodt Llc 3-oxy-hydromorphone derivatives
AU2012205733B2 (en) 2011-01-11 2015-10-08 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
SG11201401856VA (en) 2011-10-26 2014-05-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
RU2683317C2 (ru) 2014-11-25 2019-03-28 Кемфарм, Инк. Конъюгаты оксикодона с бензойной кислотой, производными бензойной кислоты и гетероарилкарбоновой кислотой

Also Published As

Publication number Publication date
US10351573B2 (en) 2019-07-16
CA2766388C (en) 2014-05-27
RU2012103476A (ru) 2013-08-10
US20150335759A1 (en) 2015-11-26
KR102038260B1 (ko) 2019-10-29
KR20180081176A (ko) 2018-07-13
EP2448407A1 (en) 2012-05-09
US20170143696A1 (en) 2017-05-25
US8461137B2 (en) 2013-06-11
US20130252994A1 (en) 2013-09-26
IL217096A0 (en) 2012-02-29
EP2448407B1 (en) 2019-09-25
US20160193204A1 (en) 2016-07-07
KR101971223B1 (ko) 2019-04-23
CN102480959A (zh) 2012-05-30
KR20170124638A (ko) 2017-11-10
BR112012000569B1 (pt) 2021-02-02
EP2448407A4 (en) 2015-06-03
IL259889A (en) 2018-07-31
US10358452B2 (en) 2019-07-23
US20150065536A1 (en) 2015-03-05
US9549923B2 (en) 2017-01-24
KR20190042115A (ko) 2019-04-23
MY153046A (en) 2014-12-31
CO6480991A2 (es) 2012-07-16
IL217096A (en) 2015-06-30
US20110002990A1 (en) 2011-01-06
US20180177883A1 (en) 2018-06-28
KR101795330B1 (ko) 2017-11-07
SG177445A1 (en) 2012-02-28
AU2010266205B2 (en) 2013-08-15
ZA201109438B (en) 2013-05-29
US10577376B2 (en) 2020-03-03
US20120142719A1 (en) 2012-06-07
US8759368B2 (en) 2014-06-24
NZ597235A (en) 2013-08-30
CL2011003347A1 (es) 2012-07-13
RU2505541C2 (ru) 2014-01-27
CN102480959B (zh) 2014-05-21
US9872915B2 (en) 2018-01-23
AU2010266205A1 (en) 2012-02-02
US9132125B2 (en) 2015-09-15
UA102916C2 (uk) 2013-08-27
CU24128B1 (es) 2015-09-29
KR101655972B1 (ko) 2016-09-08
CA2766388A1 (en) 2011-01-06
KR101877467B1 (ko) 2018-07-11
CR20110688A (es) 2012-03-22
KR20160106781A (ko) 2016-09-12
ZA201300747B (en) 2014-09-25
BR112012000569B8 (pt) 2021-05-25
KR20120048589A (ko) 2012-05-15
JP5442862B2 (ja) 2014-03-12
US20130259909A1 (en) 2013-10-03
US9650387B2 (en) 2017-05-16
US10654863B2 (en) 2020-05-19
US20180104352A1 (en) 2018-04-19
JP2012532142A (ja) 2012-12-13
US20130245265A1 (en) 2013-09-19
US20170226118A1 (en) 2017-08-10
WO2011002991A1 (en) 2011-01-06
MX2012000128A (es) 2012-04-30
US8748413B2 (en) 2014-06-10
US8828978B2 (en) 2014-09-09
EP3560336A1 (en) 2019-10-30
BR112012000569A2 (pt) 2015-09-15
US8927716B2 (en) 2015-01-06
US20150087667A1 (en) 2015-03-26
US20160200731A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
CU20110246A7 (es) Ácido benzoico, derivados de ácido benzoico y conjugados de ácido heteroaril carboxílico de hidrocodona, profármacos, métodos para elaborar y utilizar los mismos
PH12014500791A1 (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
CL2011003094A1 (es) Composicion farmaceutica semi-solida libre de agua que comprende a) un ester del acido 5-aminolevulinico (5-ala) o una sal del mismo, b) uno o mas trigliceridos y c) opcionalmente uno o mas potenciadores de viscosidad; kit farmaceutico; y su uso en el tratamiento fotodinamico del cancer, condiciones pre-cancerosas y no cancerosas asociadas a hpv.
CO2017005201A2 (es) Ácido benzóico, derivados de ácido benzóico y conjugados heteroarilcarboxílico de la oxicodona
CO6771409A2 (es) Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso
UA105229C2 (uk) Фармацевтичний склад
FR2898356B1 (fr) Diesters d'acides carboxylique ramifies
WO2011085000A3 (en) Fatty acid derivatives and analogs of drugs
WO2011123536A8 (en) Polycyclic tetracycline compounds
PH12012501552A1 (en) Therapeutic or prophylactic agent for biliary diseases
CY1111914T1 (el) Μεθοδος συνθεσης της ιβαβραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
CO2017005203A2 (es) Acido benzoico, derivados de acido benzoico y conjugados de acido carboxilico de heteroarilo de oximorfona, profarmacos, metodos de fabricacion y uso de los mismos
BRPI0814115B8 (pt) composição farmacêutica compreendendo o composto 11-deóxi-prostaglandina e método para estabilizar o composto
CY1115682T1 (el) Νεα μεθοδος συνθεσης ιβαβραδινης και των αλατων προσθηκης της με ενα φαρμακευτικως αποδεκτο οξυ
CY1115620T1 (el) Νεα μεθοδος συνθεσης ιβαμπραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
TH107166A (th) สารอนุพันธ์อิมิดาโซลิดิโนนในฐานะเป็นสารยับยั้ง 11b-HSD1
UA112329C2 (uk) Композиція проліків, що містить кон'югат аспірину з гідроморфоном, та спосіб лікування захворювання
TH152683A (th) สารประกอบไตรอะซีนในฐานะตัวยับยั้ง pi3k และ mtor
TH156236A (th) กรดเบนโซอิก, อนุพันธ์ของกรดเบนโซอิก และ เฮเทอโรเอริลคาร์บอกซิลิกแอซิด คอนจูเกตของไฮโดรมอร์โฟน, โพรดรักซ์, วิธีการทำและการใช้สารเหล่านี้ (Benzoic acid, Benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof)
CU20130078A7 (es) Ácidos 1-bencicloalquilcarboxílicos sustituidos y su uso
TH110398A (es)
HK1169273A (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
EA201201272A1 (ru) Производное пиридопиразиндиона и его применение в качестве противоязвенного средства

Legal Events

Date Code Title Description
FG Grant of patent